Related Experiment Video
Updated: May 2, 2026

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma
Published on: September 3, 2021
Navigating the Tumor Microenvironment in Colorectal Liver Metastasis: Barriers to Therapy and Emerging Opportunities
Pengtao Hu1, Junjie Sun1, Jian Lu2
1Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Abstract:
Liver metastases from colorectal cancer (CRC) are a primary cause of poor patient prognosis, closely linked to the liver's unique tumor microenvironment (TME). Compared to primary tumors, research on the TME of liver metastases remains insufficient. This review systematically summarizes recent advances in TME research concerning colorectal liver metastases (CRLM), emphasizing its organ-specific characteristics, pivotal role in tumor progression, and influence on treatment response. We delve into the intricate cellular components of the TME-including tumor-associated macrophages, cancer-associated fibroblasts, and myeloid-derived suppressor cells-and non-cellular constituents such as the extracellular matrix and soluble factors. Furthermore, we explore the multifaceted mechanisms which the TME drives CRLM progression through establishing pre-metastatic niches, facilitating cancer cell colonization, mediating immune evasion, and inducing drug resistance. Additionally, we evaluate therapeutic strategies targeting the TME, including opportunities and challenges in remodeling cellular components, modulating the extracellular matrix, and developing combination therapies. Ultimately, this review aims to provide theoretical foundations and novel insights for developing more effective anti-metastatic therapies, with the goal of improving the prognosis for CRLM patients.
Insights
This review explores the liver tumor microenvironment (TME) in colorectal cancer (CRC) liver metastases (CRLM). Understanding the TME is crucial for developing effective anti-metastatic therapies to improve patient outcomes.
Area of Science:
- Oncology
- Immunology
- Cell Biology
Background:
- Colorectal cancer (CRC) liver metastases (CRLM) significantly impact patient prognosis.
- The tumor microenvironment (TME) of CRLM is understudied but critical for tumor progression.
- Organ-specific characteristics of the liver TME influence metastasis and treatment response.
Purpose of the Study:
- To systematically review recent advances in CRLM TME research.
- To elucidate the role of cellular and non-cellular TME components in CRLM progression.
- To evaluate therapeutic strategies targeting the CRLM TME.
Main Methods:
- Systematic literature review of TME research in CRLM.
- Analysis of cellular components (e.g., macrophages, fibroblasts, suppressor cells).
- Examination of non-cellular components (e.g., extracellular matrix, soluble factors).
Main Results:
- The TME drives CRLM progression via pre-metastatic niche formation, immune evasion, and drug resistance.
- Specific cellular and non-cellular components play pivotal roles in metastasis.
- The TME significantly influences the efficacy of various treatment modalities.
Conclusions:
- Targeting the TME offers promising avenues for novel anti-metastatic therapies.
- Further research into TME remodeling and combination therapies is warranted.
- Improving understanding of the CRLM TME can enhance therapeutic strategies and patient prognosis.
More Related Videos
11:43Advanced Animal Model of Colorectal Metastasis in Liver: Imaging Techniques and Properties of Metastatic Clones
Published on: November 30, 2016
04:22Application of Laparoscopic Hepatectomy Combined with Intraoperative Microwave Ablation in Colorectal Cancer Liver Metastasis
Published on: March 3, 2023
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
The Tumor Microenvironment
The Tumor Microenvironment
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...